US20150079679A1 - Systems and methods for processing cells - Google Patents
Systems and methods for processing cells Download PDFInfo
- Publication number
- US20150079679A1 US20150079679A1 US14/547,956 US201414547956A US2015079679A1 US 20150079679 A1 US20150079679 A1 US 20150079679A1 US 201414547956 A US201414547956 A US 201414547956A US 2015079679 A1 US2015079679 A1 US 2015079679A1
- Authority
- US
- United States
- Prior art keywords
- tissue
- cutting surface
- tissue sample
- compartment
- mincing tool
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- 238000012545 processing Methods 0.000 title abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 114
- 239000012530 fluid Substances 0.000 claims description 42
- 239000007787 solid Substances 0.000 claims description 33
- 238000001914 filtration Methods 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 229940088598 enzyme Drugs 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 18
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 238000007865 diluting Methods 0.000 claims description 6
- 235000015110 jellies Nutrition 0.000 claims description 5
- 239000008274 jelly Substances 0.000 claims description 5
- 102000029816 Collagenase Human genes 0.000 claims description 4
- 108060005980 Collagenase Proteins 0.000 claims description 4
- 229960002424 collagenase Drugs 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 238000013519 translation Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 12
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000036512 infertility Effects 0.000 abstract description 5
- 239000000284 extract Substances 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 191
- 238000004062 sedimentation Methods 0.000 description 22
- 238000004891 communication Methods 0.000 description 12
- 239000011148 porous material Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 6
- 239000002577 cryoprotective agent Substances 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000003954 umbilical cord Anatomy 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 108010007093 dispase Proteins 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0236—Mechanical aspects
- A01N1/0242—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C18/00—Disintegrating by knives or other cutting or tearing members which chop material into fragments
- B02C18/06—Disintegrating by knives or other cutting or tearing members which chop material into fragments with rotating knives
- B02C18/08—Disintegrating by knives or other cutting or tearing members which chop material into fragments with rotating knives within vertical containers
- B02C18/10—Disintegrating by knives or other cutting or tearing members which chop material into fragments with rotating knives within vertical containers with drive arranged above container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C18/00—Disintegrating by knives or other cutting or tearing members which chop material into fragments
- B02C18/30—Mincing machines with perforated discs and feeding worms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M45/00—Means for pre-treatment of biological substances
- C12M45/02—Means for pre-treatment of biological substances by mechanical forces; Stirring; Trituration; Comminuting
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M45/00—Means for pre-treatment of biological substances
- C12M45/05—Means for pre-treatment of biological substances by centrifugation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M45/00—Means for pre-treatment of biological substances
- C12M45/09—Means for pre-treatment of biological substances by enzymatic treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M45/00—Means for pre-treatment of biological substances
- C12M45/22—Means for packing or storing viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Definitions
- the present invention relates to systems and methods for processing tissue to isolate and collect target cells.
- Purification of viable cells from a tissue sample can be a laborious process that involves dissection and other manual manipulation and processing steps, as well as, in some cases, cell culturing. Maintaining sterility of the cells during the purification process is also an important concern. Although laminar hoods can be used to maintain sterility, they suffer a number of disadvantages. For example, such hoods are expensive, relatively immobile, cumbersome to work with, and consume valuable laboratory space. Efficiency of the cell purification process is another concern that further complicates the purification process. Isolating rare cells, such as stem cells, from a tissue sample requires an efficient process to recover as many of the cells as possible.
- the present invention efficiently and cost-effectively extracts and collects cells from a tissue.
- the inventors have discovered that the tissue can be effectively fragmented and the resulting cells can be purified using a system or kit with multiple components.
- An advantage of the present invention is that tissue processing takes place in a closed system such that sterility can be maintained throughout the process, even if certain components are removed during processing, for example through the use of valves, clamps, and heat seals.
- any or all of the steps can be automated or manually accomplished, according to the specific needs of the application or the user.
- the invention relates to a tissue mincing tool.
- the tissue mincing tool includes a compartment for a tissue sample, a cutting surface at one end of the compartment, and a sterile, sealed container.
- the cutting surface separates the compartment from the sterile, sealed container, such that a tissue sample that passes through the cutting surface can be deposited within the container.
- the cutting surface can be dimensioned to mince the tissue sample into fragments having an average cross-section no greater than four square millimeters. For example, the number of square millimeters may be no greater than 3, 2, 1, 0.5, 0.3, 0.2, 0.1, or 0.05 in various embodiments of the invention.
- the tissue mincing tool can also include a second cutting surface for further reducing the average cross-section of the fragments.
- the cutting surface of the tissue mincing tool can include an automated cutting system.
- the cutting surface may include semi-automatic scissors.
- One or more mincer screens may be positioned in proximity to the cutting surface.
- the tissue mincing tool may further include a suction cup for stabilizing the tool during operation thereof.
- the tissue mincing tool also or alternatively can include a fluid conduit in communication with the sterile, sealed container, and a separator unit such as one or more filters within the fluid conduit.
- the sterile, sealed container optionally includes at least one sealed access port permitting the sterile introduction of a fluid into the container.
- the compartment for the tissue sample can incorporate one or more features to facilitate the application of a force to the tissue sample, impelling it beyond the cutting surface and into the sterile, sealed container.
- a portion of the compartment can be shaped to receive a solid member to press the tissue sample.
- Such a solid member can optionally be included with the tissue mincing tool, whether connected to it or provided as a separate component.
- a portion of the compartment near the cutting surface has a substantially constant cross-section, such that a comparably shaped solid member may be introduced into the compartment and fill that portion, while pressing the tissue sample into or through the cutting surface.
- the compartment near the cutting surface has a tapered or cone-shaped end.
- an interior surface of the compartment is threaded, such that a threaded solid member may be guided into the compartment.
- the compartment also includes a gasket, which can provide an improved seal when a solid member is introduced into the compartment.
- the tissue mincing tool includes a shaft crank for moving the cutting surface towards the tissue sample.
- the invention also provides methods of using any of the above-described tissue mincing tools by impelling the tissue sample through the cutting surface of the tool.
- the invention provides methods of mincing a tissue sample and optionally injecting an enzyme into the sterile, sealed container, such that the enzyme enhances the digestion of the minced tissue.
- the enzyme can be a protease, such as collagenase, hyaluronidase, or dispase, separately or in combination. These steps can optionally be incorporated into a method of separating cells from the tissue sample by mincing and/or digesting the tissue sample and removing fragments larger than about 40 microns (e.g.
- These larger fragments referred to herein as “undigested tissue,” can be removed by filtering or sedimentation.
- the methods described herein can separate cells, such as stem cells, from fat tissue or afterbirth tissue, such as placental or umbilical cord tissue or, more specifically, a tissue comprising Wharton's Jelly.
- the tissue sample is substantially free of blood vessels, which can optionally be dissected from a tissue before the tissue is placed in the compartment.
- the invention in another aspect, relates to a cell collection method including sedimenting cells in a cell collection device.
- the cell collection device includes a sterile container for a fluid including cells and a fluid passageway in communication with the sterile container.
- the fluid passageway includes a cell capture zone, such that the volume of the cell capture zone can be less than 5% of the volume of the sterile container and the sterile container and the cell capture zone can be configured such that sedimentation of the cells from the fluid in the sterile container concentrates the cells in the cell capture zone.
- This aspect or any of the following aspects can have any of the following embodiments.
- the cell collection device further includes a second sterile container in communication with the fluid passageway and/or a removable clamp to regulate passage of material into the second sterile container.
- the second sterile container can be heat-sealable and/or a bag.
- the cell collection method can also include centrifuging the cell collection device to accelerate sedimentation of the cells, and the cells can be Wharton's Jelly stem cells.
- the fluid includes mechanically minced and/or enzymatically digested umbilical cord tissue.
- the cell collection method can further include adding a cryoprotectant to the cells; the cryoprotectant includes DMSO, albumin, and/or dextran.
- the method can also include adding autologous plasma to the cells.
- the invention in still another aspect, relates to a cell collection device having a fluid including cells, a sterile container for housing the cells, and a fluid passageway in communication with the sterile container.
- the fluid passageway includes a cell capture zone, wherein the volume of the cell capture zone can be less than 5% of the volume of the sterile container and the sterile container and the cell capture zone can be configured such that sedimentation of the cells from the fluid in the sterile container concentrates the cells in the cell capture zone.
- the cell collection device also or alternatively includes a second sterile container in communication with the fluid passageway and/or a removable clamp to regulate passage of material into the second sterile container.
- the second sterile container can be heat-sealable and/or a bag.
- the invention in yet another aspect, relates to a cell collection device having a sterile container for a fluid comprising cells, such that the sterile container can be adapted for use in sedimentation, and a fluid passageway in communication with the sterile container.
- the fluid passageway includes first and second valves defining a cell capture zone therebetween, such that the volume of the cell capture zone can be less than 5% of the volume of the sterile container and the sterile container and the cell capture zone can be configured such that sedimentation of the cells from the fluid in the sterile container concentrates the cells in the cell capture zone.
- the sterile container can be adapted for use in centrifugation.
- the cell collection device also or alternatively includes a second sterile container in communication with the second valve and/or a removable clamp to regulate passage of material into the second sterile container.
- the second sterile container can be heat-sealable and/or a bag.
- the invention in still yet another aspect, relates to a cell collection device having a sterile container for housing the cells, a fluid passageway in communication with the sterile container, and a second sterile container in communication with the fluid passageway.
- the fluid passageway includes a cell capture zone, such that the volume of the cell capture zone is less than 5% of the volume of the sterile container and the sterile container and the cell capture zone can be configured such that sedimentation of the cells from the fluid in the sterile container concentrates the cells in the cell capture zone.
- the second sterile container includes an element selected from the group consisting of a bag, a heat-sealable container, and a removable clamp.
- the invention in another aspect, relates to cell collection device that includes a compartment for receiving a tissue; a cutting surface dimensioned to mince the tissue sample into fragments having an average cross-section no greater than four square millimeters; a sterile, sealed container for holding a suspension of the minced tissue, the sterile container having a volume at least ten times greater than the volume of the compartment for receiving a tissue; a filter bag in fluid communication with the sterile, sealed container; and a sedimentation bag in fluid communication with the filter bag.
- the filter bag contains at least one filter having a pore size sufficiently small to retain particles larger than about 250 ⁇ m.
- the sedimentation bag includes a tapered portion to promote the concentration of sedimented cells.
- FIG. 1 schematically depicts a tissue mincing tool, according to an embodiment of the invention
- FIG. 2 is a schematic perspective view of a solid member of a tissue mincing tool, according to an embodiment of the invention
- FIG. 3 is a schematic perspective view of the solid member of FIG. 2 ;
- FIG. 4 is a schematic perspective view partially showing a cutting surface, according to an embodiment of the invention.
- FIGS. 5A and 5B are schematic views partially showing a solid member and its complementary compartment, according to embodiments of the invention.
- FIG. 6A is a side view of a tissue mincing tool, according to another embodiment of the invention.
- FIG. 6B is a cross-sectional view along the line E-E of the tissue mincing tool of FIG. 6A ;
- FIG. 6C is an exploded view of the tissue mincing tool of FIG. 6A ;
- FIG. 7 is a schematic perspective view of a tissue mincing tool, according to yet another embodiment of the invention.
- FIG. 8 provides an overview of the procedural steps for collecting and isolating desired cells from a tissue sample, according to an embodiment of the invention
- FIG. 9 provides an overview of the procedural steps for collecting and isolating desired cells from a tissue sample, according to an embodiment of the invention.
- FIGS. 10A-10G depict procedures for collecting and isolating desired cells from a tissue sample.
- FIG. 1 schematically depicts a tissue mincing tool 10 according to one embodiment of the invention.
- the tissue mincing tool 10 includes a compartment 12 within which a tissue sample can be received and be initially housed, and a sterile, sealed container 14 .
- the compartment 12 extends between first and second ends 16 , 18 , while the sterile, sealed container 14 itself extends between first and second ends 18 , 20 .
- a cutting surface 108 is located at the second end 18 of the compartment 12 or, equivalently, at the first end 18 of the sterile, sealed container 14 , and therefore separates the compartment 12 from the sterile, sealed container 14 .
- the tissue mincing tool 10 also includes a solid member 100 .
- the solid member 100 is depicted to be partially located within (as shown in phantom) the compartment 12 . A part of the solid member 100 is also shown to be located outside the compartment 12 . Threads 105 are depicted on that exterior part of the solid member 100 .
- FIG. 2 depicts an embodiment of the solid member 100 of the tissue mincing tool 10 .
- Other portions of the tissue mincing tool 10 e.g., the compartment 12 and the sterile, sealed container 14 ) are not shown.
- the solid member 100 includes a larger diameter plunger 104 (shown with the threads 105 ) and a smaller diameter screw shaft 106 .
- a handle 114 is disposed at one end of the solid member 100 .
- the cutting surface 108 is attached to the end of the smaller diameter screw shaft 106 .
- the smaller diameter screw shaft 106 extends from the cutting surface 108 to the handle 114 (to which the smaller diameter screw shaft 106 is also coupled) and, in so doing, the smaller diameter screw shaft 106 runs through a hollow (e.g., central) portion 107 of the larger diameter plunger 104 .
- the screw shaft 106 features threads 109 along a certain length thereof and the plunger 104 includes complementary grooves 111 within its hollow portion 107 . In this way, the plunger 104 is threadably engaged with the screw shaft 106 . Accordingly, when the handle 114 is rotated, the screw shaft 106 is also caused to rotate, as is (optionally) the cutting surface 108 that is attached to the end of the screw shaft 106 .
- rotation of the screw shaft 106 causes translation of the plunger 104 , for example towards the cutting surface 108 .
- a tissue sample housed within the compartment 12 between the plunger 104 and the cutting surface 108 may thus be pressed into contact with the (optionally rotating) cutting surface 108 and, as described further below, cut thereby.
- the threaded portion 105 of the larger diameter plunger 104 can engage and mate with a complementary threaded interior portion of the compartment 12 that receives the tissue sample. Threaded engagement between the plunger 104 and the compartment 12 provides for leverage and control so that a user can more easily translate the plunger 104 within the compartment 12 using the handle 114 , as well as slide or push the tissue sample towards and through the cutting surface 108 . As illustrated in FIG. 1 , the plunger 104 is sized to mate with and substantially fill an interior hollow cavity of the compartment 12 . In an embodiment, with reference again to FIG. 2 , a gasket 118 may be disposed at one end of the plunger 104 .
- gasket 118 and plunger 104 may substantially fill an inner diameter of the interior hollow cavity of the compartment 12 , thereby creating an air-tight, vacuum seal in the compartment 12 .
- Gasket 118 may be substantially complementary in shape to cutting surface 108 .
- the bottom surface of the gasket and the top surface of the cutting surface 108 can both be round or flat.
- gasket 118 forms a flat surface. A tissue sample is impelled through cutting surface 108 and, thus, minced when gasket 118 contacts and drives the tissue sample.
- the cutting surface 108 can be any surface configured to cut, parse, or separate a tissue sample into smaller portions without damaging the cells from the tissue sample when the tissue sample is pushed through the cutting surface 108 .
- the cutting surface 108 can mince a tissue sample into smaller portions with an average cross-section no greater than four square millimeters, or one square millimeter, though cutting surfaces that can mince the tissue sample into larger or smaller portions are contemplated.
- a tissue mincing tool can include a second cutting surface to further reduce the average cross-section of the minced tissue samples.
- Examples of a cutting surface include a grate with sharp edges, multiple sharp wires across an opening, a steel plate or disc with multiple holes resting on a lip inside a compartment, holes in a plate that are offset and have a sharp edge, and a mesh of sharp surfaces defining apertures.
- an end of the plunger 104 can form multiple projections, such as fingers, that mate with the apertures of the cutting surface 108 to assist in pushing the tissue sample through the cutting surface 108 .
- the end of the plunger 104 can be flat.
- the cutting surface 108 can be textured or can form multiple projections (e.g., a cleat) to create a frictional surface or to keep the tissue sample on the cutting surface 108 as pressure is applied to the tissue sample.
- the cutting surface 108 may include an automated cutting system, such as a semi-automatic scissors.
- an optional nose nut may be disposed about the cutting surface 108 to retain the cutting surface 108 in position as a tissue sample is being impelled therethrough.
- the optional nose nut can be removably attached to the compartment 12 that receives the tissue sample.
- the optional nose nut can include a projection that engages with a recessed surface of the compartment 12 to form a snap-fit connection.
- a threaded portion of the optional nose nut can engage a similarly and complementary threaded portion of the compartment 12 .
- FIG. 3 depicts a perspective view of the solid member 100 of the tissue mincing tool 10 .
- the solid member 100 includes a larger diameter plunger 104 (shown with the threads 105 ) and a smaller diameter screw shaft 106 .
- the handle 114 is disposed at one end of the solid member 100 .
- the cutting surface 108 is attached to the end of the smaller diameter screw shaft 106 .
- the cutting surface 108 includes a cutting blade 110 adjacent a mincing disc 112 .
- FIG. 4 depicts a perspective view of an exemplary cutting surface 108 of the tissue mincing tool 10 .
- the cutting surface 108 includes the cutting blade 110 . Additionally, the cutting surface 108 includes the mincing disc 112 with apertures 116 that allow tissues samples to be impelled therethrough.
- FIGS. 5A and 5B depict two embodiments of a solid member 100 of a tissue mincing tool 10 .
- the plunger 104 of the solid member 100 is substantially cylindrical in shape near its end.
- the plunger 104 of the solid member 100 has a tapered or cone-shaped end.
- the solid member 100 is shaped to mate with and to fill the compartment 12 that is complementarily shaped, such that the solid member 100 is movable within the compartment 12 to impel a tissue sample disposed within the compartment 12 through the cutting surface 108 .
- the tissue sample passes through the cutting surface 108 , the cut portions thereof are deposited within the sterile, sealed container 14 , which may be, for example, a bag. Additionally or alternatively, the interior cavity of the compartment 12 can define a recessed channel or surface (e.g., a cam surface) to engage a projection protruding from the plunger 104 such that solid member 100 can be removably secured to the compartment 12 and the user still has leverage and control to translate the solid member 100 into the compartment 12 (not shown).
- a recessed channel or surface e.g., a cam surface
- FIG. 6A depicts a side view of a tissue mincing tool 200 according to another embodiment of the invention.
- FIG. 6B depicts a cross-sectional view along the line E-E of the tissue mincing tool 200 shown in FIG. 6A
- FIG. 6C depicts an exploded view of the tissue mincing tool 200 shown in FIG. 6A .
- the tissue mincing tool 200 includes a base 204 , a reservoir 208 , and a handle 212 .
- the base 204 may include a threaded portion 216 for threadably engaging the reservoir 208 .
- an interior surface of the reservoir 208 may feature grooves 218 that complement the threaded portion 216 of the base 204 .
- the reservoir 208 may be screwed onto the base 204 .
- a suction cup 220 may be coupled to a bottom portion 224 of the base 204 .
- the suction cup 220 provides stability for the tissue mincing tool 200 .
- a user may couple the tissue mincing tool 200 to a table (or other support surface) using the suction cup 220 . Stability is thereby provided to the tissue mincing tool 200 when, for example, the user turns the handle 212 as further described below, or otherwise imparts force to the tissue mincing tool 200 .
- a compartment 228 for initially housing a tissue sample.
- at least one cutting surface (which is coupled to the handle 212 through a shaft crack 232 ) is moveable within the reservoir 208 .
- a first cutting surface 236 , a first mincer screen 240 , a second cutting surface 244 , and a second mincer screen 248 (each of which are coupled to the handle 212 through the shaft crank 232 ) may be moveable within the reservoir 208 through actuation (e.g., rotation) of the shaft crank 232 .
- the shaft crank 232 may, for example, be manually actuated by a user via the handle 212 , or, alternatively, may be automatically machine-actuated via a separate device.
- the first and second cutting surfaces 236 , 244 may be any of the exemplary cutting surfaces described above.
- the first and second mincer screens 240 , 248 may, as illustrated, include differently-sized apertures.
- the first and second cutting surfaces 236 , 244 are likewise rotated and move downward within the reservoir 208 toward the tissue sample that is housed within the compartment 228 .
- the first cutting surface 236 makes contact with and cuts the tissue sample into one or more smaller portions. Those smaller tissue portions are then passed through the apertures of the first mincer screen 240 , are again cut into even smaller portions by the second cutting surface 244 , and are finally passed through the apertures of the second mincer screen 248 .
- the first and second cutting surfaces 236 , 244 are rotated and moved downwards within the reservoir 208 until substantially all of the tissue sample (or at least a sufficient amount of the tissue sample for a given application) is minced and passes through the second screen 248 .
- the minced tissue sample Upon passing through the second screen 248 , the minced tissue sample is collected and housed within a container 252 of the reservoir 208 .
- the top portion of the reservoir 208 may in fact be capped and the interior portion of the reservoir 208 sterilized, such that the container 252 is a sterile, sealed container 252 .
- the compartment 228 of the reservoir 208 is, as shown in FIG. 6B , located below the first and second cutting surfaces 236 , 244 and first and second mincer screens 240 , 248 , while the sterile, sealed container 252 of the reservoir 208 is located above the first and second cutting surfaces 236 , 244 and first and second mincer screens 240 , 248 .
- the sizes of the compartment 228 and of the sterile, sealed container 252 vary as the first and second cutting surfaces 236 , 244 are rotated downwards (or upwards).
- tissue mincing tool 200 in FIGS. 6A-6C is non-limiting. In fact, variations, modifications, and other implementations are contemplated. For example, fewer or more than two cutting surfaces 236 , 244 and/or two mincer screens 240 , 248 may be employed. As another example, the shaft crank 232 and handle 212 may be coupled such that the handle 212 is rotatable within a vertical plane rather than a horizontal plane (as illustrated).
- FIG. 7 depicts a tissue mincing tool 300 , according to another view of an embodiment of the invention, whose principal of operation is similar to that of the tissue mincing tool 200 depicted in FIGS. 6A-6C .
- the tissue mincing tool 300 includes a base 304 , a reservoir 308 , and a handle 312 . As shown, a top portion of the reservoir 308 is coupled to a bottom portion thereof through the use of screws 315 and wing nuts 317 .
- the tissue mincing tool 300 also includes a suction cup 320 to provide the aforedescribed stability to the tool 300 during operation.
- the container 352 of the reservoir 308 within which the minced tissue sample is collected after passing through, for example, a second screen 348 is also illustrated. As before, the top portion of the reservoir 308 may be capped and the interior portion of the reservoir 308 sterilized, such that the container 352 is a sterile, sealed container 352 .
- FIG. 8 provides an overview of the procedural steps for isolating and collecting cells.
- a tissue sample can be initially minced using any of the above-described tissue mincing tools by impelling the tissue sample through the cutting surface of the tool and into a sterile, sealed container.
- the invention also provides optional methods of further digesting the tissue sample by exposing it to a chemical or an enzyme.
- the minced tissue may be digested by injecting an enzyme into the container, such that the enzyme digests the minced tissue.
- the enzyme can be a protease, such as collagenase, hyaluronidase, or dispase, separately or in combination.
- minced and/or enzymatically digested tissue sample from any larger fragments (“undigested tissue,” as described above), for example, decanting, aspiration, sedimentation, or preferably, filtering.
- the minced and/or enzymatically digested tissue which can be viscous, is washed or diluted before a separating step.
- the separation of the target cells from the minced and/or enzymatically digested tissue can be accomplished by sedimentation of the cells from a mixture containing the minced and/or enzymatically digested tissue. Although gravity sedimentation can be used, the sedimentation process can be accelerated by, for example, centrifugation. Additionally, and alternatively, the target cells are moved into a sterile container to be cryo-preserved for later use.
- methods for separating minced and/or enzymatically digested tissue sample from undigested tissue may include two or more filtration steps as depicted in FIG. 9 .
- minced and/or enzymatically digested tissue sample may be subjected to multiple filtration steps using filters of varying sizes.
- the minced and/or enzymatically digested tissue sample is initially subjected to a first filtration step using a large-pore filter of, e.g., about 500 microns, about 250 microns, about 150 microns or about 100 microns, for removing coarse undigested tissue.
- a second filtration step can be carried out to filter the eluate from the first filtration step using a small-pore filter of, e.g., about 70 microns or about 40 microns, for removing additional contaminants such as collagen fibers.
- a small-pore filter of, e.g., about 70 microns or about 40 microns, for removing additional contaminants such as collagen fibers.
- the tissue can be washed or diluted with an appropriate sterile solution (such as a buffered salt solution) at any stage in the process.
- an appropriate sterile solution such as a buffered salt solution
- further washes can be performed to further cleanse the minced and/or enzymatically digested tissue before the second filtration step.
- target cells substantially free of tissue sample can be collected by sedimentation.
- FIG. 10A depicts an exemplary procedure for collecting and isolating desired cells from a tissue sample.
- the tissue sample may be initially placed within a compartment, where it can be minced, parsed, or separated into smaller portions.
- An advantage of mincing the tissue sample before any enzymatic digestion is that the entire surface area of the tissue sample on which the enzyme can act is increased.
- the compartment may be fitted and attached to one port (e.g., an aperture) of a container (e.g., digestion bag) such that a tissue sample introduced into the compartment can directly pass through into the container.
- the compartment may or may not be removably attached to the container.
- the container defines a sterile, sealed interior space that holds the minced tissue sample and fluids.
- the container may include sealed ports for introducing or dispensing materials and fluids into or from the container.
- the container may include one or more injection ports for introducing fluids and one or more withdrawal ports for dispensing or suction fluids and materials from the container.
- each of the injection ports and withdrawal port can be configured such that fluids and materials can only be moved in one direction to and from the container.
- the ports can be disposed at an opposite end of the container from the compartment, though the ports can also be disposed along any portion of the perimeter of the container.
- the ports are not removably secured to the container. Additionally or alternatively, syringes, air vents, capped air vents, or other devices that mate with a luer connection can be attached to the ports. All ports may be swabbable so that sterility is maintained.
- the minced tissue can optionally be digested by, for example exposing it to a chemical or an enzyme.
- the minced tissue may be digested by an enzyme, for example, a protease, such as a collagenase, hyaluronidase, or dispase, separately or in combination.
- the enzyme may be directly introduced into the container, such that the enzyme digests the minced tissue.
- a syringe, or any other device that can house fluids, materials, or air can be connected to the container (e.g., via a luer connection) and used to dispense, for example, a protease into the container to digest the minced tissue sample.
- the container can be inverted to circulate the enzyme about the container.
- the container can be placed at rest and the minced tissue sample can be incubated with the enzyme at 37° C. for a period of time, for example, for about one to three hours, though more or less time is contemplated, to digest the minced tissue sample.
- the container can optionally be periodically mixed with an orbital shaker or moved through a series of rollers or other compression-type device to assist in the break-down of the minced tissue sample within the container.
- tissue sample is about 10 mL
- a user can inject about 10 mL of enzyme into the container, though more or less enzyme is contemplated.
- a digested tissue sample of about 20-30 mL results.
- any remaining fragments of undigested tissue are optionally removed to facilitate the subsequent purification of the cells.
- undigested tissue can be removed by, for example, physical extraction, decanting, aspiration, sedimentation, or preferably, filtering.
- the undigested tissue that is removed may be stored and/or used for other purposes such as a seeding source for the expansion of stem cells.
- FIGS. 10A-10D illustrate various embodiments in which separation is achieved by filtration.
- FIGS. 10A-10D depict a fluid passageway that connects the container holding the digested tissue sample to a filter unit which can be removably attached to the container.
- the filter unit may use a single filter, or a plurality of filters, optionally of decreasing size.
- a filter may be fitted and disposed in the container such that that the container is divided into two sub-spaces.
- the filter may be symmetrically or asymmetrically placed within the container.
- the filter may be fitted within a port, for example, a withdrawal port.
- the size of the filter can be about 500 microns, about 250 microns, about 150 microns, about 100 microns, about 70 microns, about 40 microns, or any range thereof, depending on the application.
- the digested tissue sample which can be viscous, may be diluted prior to filtering so that the resultant tissue sample can more easily move through the filter into downstream containers or components for further processing.
- diluting solutions include phosphate buffered saline (PBS), 5% human serum albumin, saline, heta-starch, and fresh plasma (e.g., autologous plasma).
- a syringe or any other device that can house fluids, is used to dispense a diluting solution into the container via an injection port.
- the digested tissue sample is about 20-30 mL
- a user can inject about 250 mL of a diluting solution into the container, though more or less solution is contemplated.
- the container holds about 250-300 mL of a diluted, digested tissue sample.
- the eluate may be propelled, e.g., by vacuum, suction, or gravity, into a second sterile container (e.g., a wash/centrifugation bag) via a fluid passageway preferably regulated by line clamps (e.g., butterfly line clamps).
- a second sterile container e.g., a wash/centrifugation bag
- line clamps e.g., butterfly line clamps
- Isolating cells from diluted, minced and/or enzymatically digested tissue can be accomplished by various mechanisms.
- the target cells are isolated from the diluted, minced and/or enzymatically digested tissue by sedimentation.
- gravity sedimentation can be used, the sedimentation process can be accelerated by, for example, centrifugation.
- the present invention can include customized centrifuge buckets, inserts, and balance weights to ensure proper centrifuge of the system.
- Sedimentation separates the target cells from the diluted, minced and/or enzymatically digested tissue sample.
- supernatants substantially free of cells are optionally removed via an outlet port and a fluid passageway preferably regulated by line clamps.
- the supernatant may be removed by, for example, decanting or aspiration.
- the second sterile container is a compressible bag
- the supernatant may be decanted by physically pressing the bag.
- the supernatant may be removed, e.g., by vacuum, suction, or gravity.
- the supernatant can be removed into a waste container that is connected to the second sterile container through an outlet port and a fluid passageway regulated by line clamps.
- the removed supernatant may be stored and/or used for other purposes such as maintaining cells (in culture).
- a small volume of a diluting solution e.g., 20 ml of autologous plasma
- a diluting solution e.g., 20 ml of autologous plasma
- the second sterile container can have a bottom that is tapered to an angle sufficient to facilitate movement of the target cells into a fluid passageway located at the bottom of the container, and optionally into a transfer container (e.g., transfer bag).
- a transfer container e.g., transfer bag
- target cells may be moved into a fluid passageway located at the side of the container, and optionally into a transfer container. Movement of the cells out of the second sterile container and into the fluid passageway and optionally into a transfer container can be facilitated by vacuum or suction and may be regulated by line clamps.
- the purified, target cells can be used immediately. Typically, however, the cells are cryopreserved for later use.
- cells can be transferred from the optional transfer container into a sealable, sterile container amenable to freezing (e.g., cryo-bag).
- cryo-bag a sealable, sterile container amenable to freezing
- cells can be directly collected from the second sterile container into a freezable container for later use.
- Cryoprotectants are added to assist in storage and preservation of target cells, and can include, for example, dimethyl sulfoxide (DMSO), albumin, and/or dextran, separately or in combination.
- Cryoprotectants may be added to the cells within the second sterile container following sedimentation.
- cryoprotectants may be added to and mixed with the cells within the optional transfer container or within the freezable container for long-term storage and later use.
- methods for separating minced and/or enzymatically digested tissue from undigested tissue may include two or more filtration steps as depicted in FIGS. 10C-10D .
- minced and/or enzymatically digested tissue may be subjected to a first filtration step to remove coarse, undigested tissue. Because the minced and/or enzymatically digested tissue is generally viscous, the tissue can be washed or diluted with an appropriate sterile solution at any stage in the process. For example, after the minced and/or enzymatically digested tissue has been separated from the undigested tissue following the first filtration step, further washes can be performed to further cleanse the tissue prior to a second filtration step.
- the second filtration step may utilize a smaller sized filter in order to remove contaminants such as collagen fibers from the minced and/or enzymatically digested tissue.
- target cells may be collected by sedimentation and moved into an optional transfer bag through a fluid passageway located either at the bottom of the container ( FIG. 10C ) or at the side of the container ( FIG. 10D ).
- the cells may be directly collected into a sterile cryo-bag for long-term storage and later use.
- FIGS. 10E-10G Additional exemplary processes for separating minced tissue samples are depicted in FIGS. 10E-10G .
- a tissue sample is placed in a mincer, such as the mincer of FIG. 7 .
- the mincer forces the tissue sample through one or more cutting surfaces and deposits the finely minced tissue on the other side of the cutting surface(s).
- a saline bag is provided to permit the flushing of the tissue out of the mincer; typically, up to 500 mL of saline may be used for this purpose.
- the minced tissue may flow into an optional digestion bag (as shown), where the minced tissue may be enzymatically digested (as described with reference to FIGS. 10A-10D ) prior to further processing.
- the optional digestion bag is in fluid communication with a dilution bag.
- the minced tissue can flow directly into a dilution bag.
- the mechanically minced tissue may be viscous.
- the dilution bag can be mechanically manipulated to encourage the mixing of the tissue and the saline.
- the dilution bag is also fitted with an optional injection port, permitting the injection of additional saline into the dilution bag as required.
- FIGS. 10E-G the suspension passes from the dilution bag into a filter bag having at least one in-bag filter.
- FIG. 10E depicts an embodiment with a single in-bag filter which retains particles larger than about 40-70 ⁇ m.
- FIG. 1 OF depicts an embodiment with a single in-bag filter which retains particles larger than about 150-250 ⁇ m.
- the filtrate from the in-bag filter then passes through a second, in-line filter unit which retains particles larger than about 40-70 ⁇ m.
- the filter bag contains two in-bag filters in succession, each in-bag filter having a surface area of at least 300 cm 2 ; the first filter retains particles larger than about 500 ⁇ m and the second filter retains particles larger than about 100 ⁇ m.
- the filter bag includes a port permitting the removal of the retentate from the first filter. This retentate can optionally be used as a tissue explant for culturing cells.
- FIGS. 10E-G pass into a centrifugation bag like those depicted in FIGS. 10A-D .
- Cells are separated from the suspension by sedimentation (e.g. by centrifugation) and are concentrated in the bottom portion of the bag, or in a fluid passageway connected to the bottom portion of the bag.
- the supernatant can be removed (e.g. by decanting, aspiration, vacuum, suction, or by compressing the bag) through tubing optionally connected to a waste container.
- the supernatant may be used for other purposes such as maintaining cells in culture.
- a small volume of a diluting solution (e.g., 20 ml of autologous plasma) can be added to resuspend sedimented cells.
- a diluting solution e.g. 20 ml of autologous plasma
- the resuspended cells can pass from the centrifugation bag into a transfer bag, optionally after passing through a second filter bag, such as a second filter bag containing a filter having a surface area of at least 100 cm 2 and retaining particles greater than about 40 ⁇ m, as shown in FIG. 10G .
- the cells can be transferred to a cryobag and one or more cryoprotectants can be added, such as DMSO, albumin, and/or dextran, as described above for FIGS. 10A-D .
- the methods described herein are effective for purifying cells from a variety of solid tissues.
- the methods described herein can separate cells, such as stem cells, from fat tissue or afterbirth tissue, such as placenta or umbilical cord tissue or, more specifically, a tissue comprising Wharton's Jelly.
- the purified Wharton's Jelly stem cells can be used to treat or regenerate any of a variety of tissues such as bone, cartilage, fat or muscle. These cells can also facilitate hematopoietic engraftment and have the potential to regulate and suppress immune responses in a host.
- the methods described herein also yield additional useful products.
- the remaining, cell-depleted tissue is a rich, sterile solution that can be used for maintaining cells (in culture, for example).
- any fragments of undigested tissue remaining after a digestion process can also be useful.
- undigested umbilical cord tissue can be utilized as a seeding source for the expansion of mesenchymal stem cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Sustainable Development (AREA)
- Molecular Biology (AREA)
- Mechanical Engineering (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Food Science & Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Sampling And Sample Adjustment (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- This application is a continuation of, claims priority to and the benefit of, and incorporates herein by reference in its entirety U.S. patent application Ser. No. 13/933,034, which was filed on Jul. 1, 2013 and issued on Nov. 25, 2014 as U.S. Pat. No. 8,893,995. U.S. patent application Ser. No. 13/933,034 is a continuation of International Patent Application No. PCT/US2012/064130, which was filed on Nov. 8, 2012 and which itself claims priority to and the benefit of U.S. Provisional Patent Application No. 61/557,127, which was filed on Nov. 8, 2011. The contents of International Patent Application No. PCT/US2012/064130 and U.S. Provisional Patent Application No. 61/557,127 are also incorporated herein by reference in their entirety.
- In various embodiments, the present invention relates to systems and methods for processing tissue to isolate and collect target cells.
- Purification of viable cells from a tissue sample can be a laborious process that involves dissection and other manual manipulation and processing steps, as well as, in some cases, cell culturing. Maintaining sterility of the cells during the purification process is also an important concern. Although laminar hoods can be used to maintain sterility, they suffer a number of disadvantages. For example, such hoods are expensive, relatively immobile, cumbersome to work with, and consume valuable laboratory space. Efficiency of the cell purification process is another concern that further complicates the purification process. Isolating rare cells, such as stem cells, from a tissue sample requires an efficient process to recover as many of the cells as possible.
- There remains a need for a practical, cost-effective, sterile, and efficient mechanism and method for extracting and collecting cells, such as stem cells, for advancing potential therapies that rely on the administration of these cells.
- The present invention efficiently and cost-effectively extracts and collects cells from a tissue. The inventors have discovered that the tissue can be effectively fragmented and the resulting cells can be purified using a system or kit with multiple components. An advantage of the present invention is that tissue processing takes place in a closed system such that sterility can be maintained throughout the process, even if certain components are removed during processing, for example through the use of valves, clamps, and heat seals. Furthermore, any or all of the steps can be automated or manually accomplished, according to the specific needs of the application or the user.
- Thus, in one aspect, the invention relates to a tissue mincing tool. The tissue mincing tool includes a compartment for a tissue sample, a cutting surface at one end of the compartment, and a sterile, sealed container. The cutting surface separates the compartment from the sterile, sealed container, such that a tissue sample that passes through the cutting surface can be deposited within the container. The cutting surface can be dimensioned to mince the tissue sample into fragments having an average cross-section no greater than four square millimeters. For example, the number of square millimeters may be no greater than 3, 2, 1, 0.5, 0.3, 0.2, 0.1, or 0.05 in various embodiments of the invention. The tissue mincing tool can also include a second cutting surface for further reducing the average cross-section of the fragments. The cutting surface of the tissue mincing tool can include an automated cutting system. For example, the cutting surface may include semi-automatic scissors. One or more mincer screens may be positioned in proximity to the cutting surface. The tissue mincing tool may further include a suction cup for stabilizing the tool during operation thereof. The tissue mincing tool also or alternatively can include a fluid conduit in communication with the sterile, sealed container, and a separator unit such as one or more filters within the fluid conduit. The sterile, sealed container optionally includes at least one sealed access port permitting the sterile introduction of a fluid into the container.
- In the tissue mincing tool, the compartment for the tissue sample can incorporate one or more features to facilitate the application of a force to the tissue sample, impelling it beyond the cutting surface and into the sterile, sealed container. For example, a portion of the compartment can be shaped to receive a solid member to press the tissue sample. Such a solid member can optionally be included with the tissue mincing tool, whether connected to it or provided as a separate component.
- In one embodiment, a portion of the compartment near the cutting surface has a substantially constant cross-section, such that a comparably shaped solid member may be introduced into the compartment and fill that portion, while pressing the tissue sample into or through the cutting surface. In another embodiment, the compartment near the cutting surface has a tapered or cone-shaped end. In some embodiments, an interior surface of the compartment is threaded, such that a threaded solid member may be guided into the compartment. In some embodiments, the compartment also includes a gasket, which can provide an improved seal when a solid member is introduced into the compartment. In yet another embodiment, the tissue mincing tool includes a shaft crank for moving the cutting surface towards the tissue sample.
- The invention also provides methods of using any of the above-described tissue mincing tools by impelling the tissue sample through the cutting surface of the tool. The invention provides methods of mincing a tissue sample and optionally injecting an enzyme into the sterile, sealed container, such that the enzyme enhances the digestion of the minced tissue. The enzyme can be a protease, such as collagenase, hyaluronidase, or dispase, separately or in combination. These steps can optionally be incorporated into a method of separating cells from the tissue sample by mincing and/or digesting the tissue sample and removing fragments larger than about 40 microns (e.g. fragments retained by a filter having a pore size of about 500 microns, or fragments retained by a filter having a pore size of about 300 microns, or fragments retained by a filter having a pore size of about 250 microns, or fragments retained by a filter having a pore size of about 150 microns, or fragments retained by a filter having a pore size of about 100 microns, or fragments retained by a filter having a pore size of about 70 microns, or fragments retained by a filter having a pore size of about 40 microns). These larger fragments, referred to herein as “undigested tissue,” can be removed by filtering or sedimentation. These methods are effective for purifying cells from any of a variety of solid tissues. For example, the methods described herein can separate cells, such as stem cells, from fat tissue or afterbirth tissue, such as placental or umbilical cord tissue or, more specifically, a tissue comprising Wharton's Jelly. In some embodiments, the tissue sample is substantially free of blood vessels, which can optionally be dissected from a tissue before the tissue is placed in the compartment.
- In another aspect, the invention relates to a cell collection method including sedimenting cells in a cell collection device. The cell collection device includes a sterile container for a fluid including cells and a fluid passageway in communication with the sterile container. The fluid passageway includes a cell capture zone, such that the volume of the cell capture zone can be less than 5% of the volume of the sterile container and the sterile container and the cell capture zone can be configured such that sedimentation of the cells from the fluid in the sterile container concentrates the cells in the cell capture zone. This aspect or any of the following aspects can have any of the following embodiments. The cell collection device further includes a second sterile container in communication with the fluid passageway and/or a removable clamp to regulate passage of material into the second sterile container. The second sterile container can be heat-sealable and/or a bag. The cell collection method can also include centrifuging the cell collection device to accelerate sedimentation of the cells, and the cells can be Wharton's Jelly stem cells. The fluid includes mechanically minced and/or enzymatically digested umbilical cord tissue. The cell collection method can further include adding a cryoprotectant to the cells; the cryoprotectant includes DMSO, albumin, and/or dextran. The method can also include adding autologous plasma to the cells.
- In still another aspect, the invention relates to a cell collection device having a fluid including cells, a sterile container for housing the cells, and a fluid passageway in communication with the sterile container. The fluid passageway includes a cell capture zone, wherein the volume of the cell capture zone can be less than 5% of the volume of the sterile container and the sterile container and the cell capture zone can be configured such that sedimentation of the cells from the fluid in the sterile container concentrates the cells in the cell capture zone. This aspect or any of the following aspects can have any of the following embodiments. The cell collection device also or alternatively includes a second sterile container in communication with the fluid passageway and/or a removable clamp to regulate passage of material into the second sterile container. The second sterile container can be heat-sealable and/or a bag.
- In yet another aspect, the invention relates to a cell collection device having a sterile container for a fluid comprising cells, such that the sterile container can be adapted for use in sedimentation, and a fluid passageway in communication with the sterile container. The fluid passageway includes first and second valves defining a cell capture zone therebetween, such that the volume of the cell capture zone can be less than 5% of the volume of the sterile container and the sterile container and the cell capture zone can be configured such that sedimentation of the cells from the fluid in the sterile container concentrates the cells in the cell capture zone. This aspect or any of the following aspects can have any of the following embodiments. The sterile container can be adapted for use in centrifugation. The cell collection device also or alternatively includes a second sterile container in communication with the second valve and/or a removable clamp to regulate passage of material into the second sterile container. The second sterile container can be heat-sealable and/or a bag.
- In still yet another aspect, the invention relates to a cell collection device having a sterile container for housing the cells, a fluid passageway in communication with the sterile container, and a second sterile container in communication with the fluid passageway. The fluid passageway includes a cell capture zone, such that the volume of the cell capture zone is less than 5% of the volume of the sterile container and the sterile container and the cell capture zone can be configured such that sedimentation of the cells from the fluid in the sterile container concentrates the cells in the cell capture zone. The second sterile container includes an element selected from the group consisting of a bag, a heat-sealable container, and a removable clamp.
- In another aspect, the invention relates to cell collection device that includes a compartment for receiving a tissue; a cutting surface dimensioned to mince the tissue sample into fragments having an average cross-section no greater than four square millimeters; a sterile, sealed container for holding a suspension of the minced tissue, the sterile container having a volume at least ten times greater than the volume of the compartment for receiving a tissue; a filter bag in fluid communication with the sterile, sealed container; and a sedimentation bag in fluid communication with the filter bag. The filter bag contains at least one filter having a pore size sufficiently small to retain particles larger than about 250 μm. The sedimentation bag includes a tapered portion to promote the concentration of sedimented cells.
- Other features and advantages of the present invention, as well as the invention itself, can be more fully understood from the following description of the various embodiments, when read together with the accompanying drawings, in which:
-
FIG. 1 schematically depicts a tissue mincing tool, according to an embodiment of the invention; -
FIG. 2 is a schematic perspective view of a solid member of a tissue mincing tool, according to an embodiment of the invention; -
FIG. 3 is a schematic perspective view of the solid member ofFIG. 2 ; -
FIG. 4 is a schematic perspective view partially showing a cutting surface, according to an embodiment of the invention; -
FIGS. 5A and 5B are schematic views partially showing a solid member and its complementary compartment, according to embodiments of the invention; -
FIG. 6A is a side view of a tissue mincing tool, according to another embodiment of the invention; -
FIG. 6B is a cross-sectional view along the line E-E of the tissue mincing tool ofFIG. 6A ; -
FIG. 6C is an exploded view of the tissue mincing tool ofFIG. 6A ; -
FIG. 7 is a schematic perspective view of a tissue mincing tool, according to yet another embodiment of the invention; -
FIG. 8 provides an overview of the procedural steps for collecting and isolating desired cells from a tissue sample, according to an embodiment of the invention; -
FIG. 9 provides an overview of the procedural steps for collecting and isolating desired cells from a tissue sample, according to an embodiment of the invention; and -
FIGS. 10A-10G depict procedures for collecting and isolating desired cells from a tissue sample. - To provide an overall understanding of the invention, certain illustrative embodiments will now be described, including systems and methods for processing cells. However, it will be understood by one of ordinary skill in the art that the systems and methods described herein may be adapted and modified as is appropriate for the application being addressed and that the systems and methods described herein may be employed in other suitable applications. All such adaptations and modifications are to be considered within the scope of the invention. Furthermore, it is to be understood that the features of the various embodiments described herein are not mutually exclusive and can exist in various combinations and permutations.
-
FIG. 1 schematically depicts atissue mincing tool 10 according to one embodiment of the invention. Thetissue mincing tool 10 includes acompartment 12 within which a tissue sample can be received and be initially housed, and a sterile, sealedcontainer 14. Thecompartment 12 extends between first and second ends 16, 18, while the sterile, sealedcontainer 14 itself extends between first and second ends 18, 20. A cuttingsurface 108 is located at thesecond end 18 of thecompartment 12 or, equivalently, at thefirst end 18 of the sterile, sealedcontainer 14, and therefore separates thecompartment 12 from the sterile, sealedcontainer 14. As illustrated, thetissue mincing tool 10 also includes asolid member 100. Thesolid member 100 is depicted to be partially located within (as shown in phantom) thecompartment 12. A part of thesolid member 100 is also shown to be located outside thecompartment 12.Threads 105 are depicted on that exterior part of thesolid member 100. -
FIG. 2 depicts an embodiment of thesolid member 100 of thetissue mincing tool 10. Other portions of the tissue mincing tool 10 (e.g., thecompartment 12 and the sterile, sealed container 14) are not shown. Thesolid member 100 includes a larger diameter plunger 104 (shown with the threads 105) and a smallerdiameter screw shaft 106. Ahandle 114 is disposed at one end of thesolid member 100. At the opposite end of thesolid member 100, the cuttingsurface 108 is attached to the end of the smallerdiameter screw shaft 106. As illustrated, the smallerdiameter screw shaft 106 extends from the cuttingsurface 108 to the handle 114 (to which the smallerdiameter screw shaft 106 is also coupled) and, in so doing, the smallerdiameter screw shaft 106 runs through a hollow (e.g., central)portion 107 of thelarger diameter plunger 104. In one embodiment, thescrew shaft 106 featuresthreads 109 along a certain length thereof and theplunger 104 includescomplementary grooves 111 within itshollow portion 107. In this way, theplunger 104 is threadably engaged with thescrew shaft 106. Accordingly, when thehandle 114 is rotated, thescrew shaft 106 is also caused to rotate, as is (optionally) thecutting surface 108 that is attached to the end of thescrew shaft 106. Moreover, rotation of thescrew shaft 106 causes translation of theplunger 104, for example towards the cuttingsurface 108. A tissue sample housed within thecompartment 12 between theplunger 104 and the cuttingsurface 108 may thus be pressed into contact with the (optionally rotating) cuttingsurface 108 and, as described further below, cut thereby. - The threaded
portion 105 of thelarger diameter plunger 104 can engage and mate with a complementary threaded interior portion of thecompartment 12 that receives the tissue sample. Threaded engagement between theplunger 104 and thecompartment 12 provides for leverage and control so that a user can more easily translate theplunger 104 within thecompartment 12 using thehandle 114, as well as slide or push the tissue sample towards and through the cuttingsurface 108. As illustrated inFIG. 1 , theplunger 104 is sized to mate with and substantially fill an interior hollow cavity of thecompartment 12. In an embodiment, with reference again toFIG. 2 , agasket 118 may be disposed at one end of theplunger 104. Together, thegasket 118 andplunger 104 may substantially fill an inner diameter of the interior hollow cavity of thecompartment 12, thereby creating an air-tight, vacuum seal in thecompartment 12.Gasket 118 may be substantially complementary in shape to cuttingsurface 108. For example, the bottom surface of the gasket and the top surface of the cuttingsurface 108 can both be round or flat. In an embodiment,gasket 118 forms a flat surface. A tissue sample is impelled through cuttingsurface 108 and, thus, minced whengasket 118 contacts and drives the tissue sample. - The cutting
surface 108 can be any surface configured to cut, parse, or separate a tissue sample into smaller portions without damaging the cells from the tissue sample when the tissue sample is pushed through the cuttingsurface 108. For example, the cuttingsurface 108 can mince a tissue sample into smaller portions with an average cross-section no greater than four square millimeters, or one square millimeter, though cutting surfaces that can mince the tissue sample into larger or smaller portions are contemplated. A tissue mincing tool can include a second cutting surface to further reduce the average cross-section of the minced tissue samples. Examples of a cutting surface include a grate with sharp edges, multiple sharp wires across an opening, a steel plate or disc with multiple holes resting on a lip inside a compartment, holes in a plate that are offset and have a sharp edge, and a mesh of sharp surfaces defining apertures. Additionally or alternatively, in an embodiment in which a cutting surface defines apertures, an end of theplunger 104 can form multiple projections, such as fingers, that mate with the apertures of the cuttingsurface 108 to assist in pushing the tissue sample through the cuttingsurface 108. In an alternative embodiment, the end of theplunger 104 can be flat. Moreover, the cuttingsurface 108 can be textured or can form multiple projections (e.g., a cleat) to create a frictional surface or to keep the tissue sample on the cuttingsurface 108 as pressure is applied to the tissue sample. In a further embodiment, the cuttingsurface 108 may include an automated cutting system, such as a semi-automatic scissors. - In an embodiment, an optional nose nut (not shown) may be disposed about the cutting
surface 108 to retain the cuttingsurface 108 in position as a tissue sample is being impelled therethrough. For example, the optional nose nut can be removably attached to thecompartment 12 that receives the tissue sample. The optional nose nut can include a projection that engages with a recessed surface of thecompartment 12 to form a snap-fit connection. Additionally or alternatively, a threaded portion of the optional nose nut can engage a similarly and complementary threaded portion of thecompartment 12. When the optional nose nut is fully engaged with thecompartment 12, the cuttingsurface 108 is disposed on and retained in position by a lip of the optional nose nut. -
FIG. 3 depicts a perspective view of thesolid member 100 of thetissue mincing tool 10. Other portions of the tissue mincing tool (e.g., thecompartment 12 and the sterile, sealed container 14) are not shown. As before, thesolid member 100 includes a larger diameter plunger 104 (shown with the threads 105) and a smallerdiameter screw shaft 106. Thehandle 114 is disposed at one end of thesolid member 100. At the opposite end of thesolid member 100, the cuttingsurface 108 is attached to the end of the smallerdiameter screw shaft 106. In one embodiment, as illustrated, the cuttingsurface 108 includes acutting blade 110 adjacent amincing disc 112. -
FIG. 4 depicts a perspective view of anexemplary cutting surface 108 of thetissue mincing tool 10. The cuttingsurface 108 includes thecutting blade 110. Additionally, the cuttingsurface 108 includes themincing disc 112 withapertures 116 that allow tissues samples to be impelled therethrough. -
FIGS. 5A and 5B depict two embodiments of asolid member 100 of atissue mincing tool 10. In one embodiment depicted inFIG. 5A , theplunger 104 of thesolid member 100 is substantially cylindrical in shape near its end. In a second embodiment depicted inFIG. 5B , theplunger 104 of thesolid member 100 has a tapered or cone-shaped end. In each embodiment, thesolid member 100 is shaped to mate with and to fill thecompartment 12 that is complementarily shaped, such that thesolid member 100 is movable within thecompartment 12 to impel a tissue sample disposed within thecompartment 12 through the cuttingsurface 108. As the tissue sample passes through the cuttingsurface 108, the cut portions thereof are deposited within the sterile, sealedcontainer 14, which may be, for example, a bag. Additionally or alternatively, the interior cavity of thecompartment 12 can define a recessed channel or surface (e.g., a cam surface) to engage a projection protruding from theplunger 104 such thatsolid member 100 can be removably secured to thecompartment 12 and the user still has leverage and control to translate thesolid member 100 into the compartment 12 (not shown). -
FIG. 6A depicts a side view of atissue mincing tool 200 according to another embodiment of the invention.FIG. 6B depicts a cross-sectional view along the line E-E of thetissue mincing tool 200 shown inFIG. 6A , whileFIG. 6C depicts an exploded view of thetissue mincing tool 200 shown inFIG. 6A . Thetissue mincing tool 200 includes abase 204, areservoir 208, and ahandle 212. As shown, thebase 204 may include a threadedportion 216 for threadably engaging thereservoir 208. For example, an interior surface of thereservoir 208 may featuregrooves 218 that complement the threadedportion 216 of thebase 204. Thus, during assembly of thetissue mincing tool 200, thereservoir 208 may be screwed onto thebase 204. - As illustrated, a
suction cup 220 may be coupled to abottom portion 224 of thebase 204. In one embodiment, thesuction cup 220 provides stability for thetissue mincing tool 200. For example, in operation, a user may couple thetissue mincing tool 200 to a table (or other support surface) using thesuction cup 220. Stability is thereby provided to thetissue mincing tool 200 when, for example, the user turns thehandle 212 as further described below, or otherwise imparts force to thetissue mincing tool 200. - As most clearly shown in
FIG. 6B , included within thereservoir 208 is acompartment 228 for initially housing a tissue sample. In addition, at least one cutting surface (which is coupled to thehandle 212 through a shaft crack 232) is moveable within thereservoir 208. For example, as most clearly shown inFIG. 6C , afirst cutting surface 236, afirst mincer screen 240, asecond cutting surface 244, and a second mincer screen 248 (each of which are coupled to thehandle 212 through the shaft crank 232) may be moveable within thereservoir 208 through actuation (e.g., rotation) of the shaft crank 232. The shaft crank 232 may, for example, be manually actuated by a user via thehandle 212, or, alternatively, may be automatically machine-actuated via a separate device. As will be understood by one of ordinary skill in the art, the first and second cutting surfaces 236, 244 may be any of the exemplary cutting surfaces described above. In addition, the first and second mincer screens 240, 248 may, as illustrated, include differently-sized apertures. - In operation, as the shaft crank 232 is rotated, the first and second cutting surfaces 236, 244 are likewise rotated and move downward within the
reservoir 208 toward the tissue sample that is housed within thecompartment 228. Thefirst cutting surface 236 makes contact with and cuts the tissue sample into one or more smaller portions. Those smaller tissue portions are then passed through the apertures of thefirst mincer screen 240, are again cut into even smaller portions by thesecond cutting surface 244, and are finally passed through the apertures of thesecond mincer screen 248. The first and second cutting surfaces 236, 244 are rotated and moved downwards within thereservoir 208 until substantially all of the tissue sample (or at least a sufficient amount of the tissue sample for a given application) is minced and passes through thesecond screen 248. Upon passing through thesecond screen 248, the minced tissue sample is collected and housed within acontainer 252 of thereservoir 208. Although not depicted as such inFIGS. 6A-6C , the top portion of thereservoir 208 may in fact be capped and the interior portion of thereservoir 208 sterilized, such that thecontainer 252 is a sterile, sealedcontainer 252. - As will be understood by one of ordinary skill in the art, and as described above, the
compartment 228 of thereservoir 208 is, as shown inFIG. 6B , located below the first and second cutting surfaces 236, 244 and first and second mincer screens 240, 248, while the sterile, sealedcontainer 252 of thereservoir 208 is located above the first and second cutting surfaces 236, 244 and first and second mincer screens 240, 248. As such, in the embodiment of thetissue mincing tool 200 depicted inFIGS. 6A-6C , the sizes of thecompartment 228 and of the sterile, sealedcontainer 252 vary as the first and second cutting surfaces 236, 244 are rotated downwards (or upwards). - As will also be understood by one of ordinary skill in the art, the depiction of the
tissue mincing tool 200 inFIGS. 6A-6C is non-limiting. In fact, variations, modifications, and other implementations are contemplated. For example, fewer or more than two cuttingsurfaces mincer screens handle 212 is rotatable within a vertical plane rather than a horizontal plane (as illustrated). -
FIG. 7 depicts atissue mincing tool 300, according to another view of an embodiment of the invention, whose principal of operation is similar to that of thetissue mincing tool 200 depicted inFIGS. 6A-6C . As before, thetissue mincing tool 300 includes abase 304, areservoir 308, and ahandle 312. As shown, a top portion of thereservoir 308 is coupled to a bottom portion thereof through the use ofscrews 315 and wing nuts 317. Thetissue mincing tool 300 also includes asuction cup 320 to provide the aforedescribed stability to thetool 300 during operation. Thecontainer 352 of thereservoir 308 within which the minced tissue sample is collected after passing through, for example, a second screen 348 is also illustrated. As before, the top portion of thereservoir 308 may be capped and the interior portion of thereservoir 308 sterilized, such that thecontainer 352 is a sterile, sealedcontainer 352. - The invention also provides methods for efficient and sterile processing of tissue to isolate and to collect target cells.
FIG. 8 provides an overview of the procedural steps for isolating and collecting cells. Generally, a tissue sample can be initially minced using any of the above-described tissue mincing tools by impelling the tissue sample through the cutting surface of the tool and into a sterile, sealed container. The invention also provides optional methods of further digesting the tissue sample by exposing it to a chemical or an enzyme. For example, the minced tissue may be digested by injecting an enzyme into the container, such that the enzyme digests the minced tissue. The enzyme can be a protease, such as collagenase, hyaluronidase, or dispase, separately or in combination. These steps are additionally or optionally incorporated into a method of separating minced and/or enzymatically digested tissue sample from any larger fragments (“undigested tissue,” as described above), for example, decanting, aspiration, sedimentation, or preferably, filtering. In some embodiments, the minced and/or enzymatically digested tissue, which can be viscous, is washed or diluted before a separating step. The separation of the target cells from the minced and/or enzymatically digested tissue can be accomplished by sedimentation of the cells from a mixture containing the minced and/or enzymatically digested tissue. Although gravity sedimentation can be used, the sedimentation process can be accelerated by, for example, centrifugation. Additionally, and alternatively, the target cells are moved into a sterile container to be cryo-preserved for later use. - In an embodiment, methods for separating minced and/or enzymatically digested tissue sample from undigested tissue may include two or more filtration steps as depicted in
FIG. 9 . For example, minced and/or enzymatically digested tissue sample may be subjected to multiple filtration steps using filters of varying sizes. In an embodiment, the minced and/or enzymatically digested tissue sample is initially subjected to a first filtration step using a large-pore filter of, e.g., about 500 microns, about 250 microns, about 150 microns or about 100 microns, for removing coarse undigested tissue. Additionally, a second filtration step can be carried out to filter the eluate from the first filtration step using a small-pore filter of, e.g., about 70 microns or about 40 microns, for removing additional contaminants such as collagen fibers. Because the minced and/or enzymatically digested tissue is generally viscous, the tissue can be washed or diluted with an appropriate sterile solution (such as a buffered salt solution) at any stage in the process. For example, after the minced and/or enzymatically digested tissue has been separated from the undigested tissue following the first filtration step, further washes can be performed to further cleanse the minced and/or enzymatically digested tissue before the second filtration step. Following multiple rounds of filtration, target cells substantially free of tissue sample can be collected by sedimentation. -
FIG. 10A depicts an exemplary procedure for collecting and isolating desired cells from a tissue sample. The tissue sample may be initially placed within a compartment, where it can be minced, parsed, or separated into smaller portions. An advantage of mincing the tissue sample before any enzymatic digestion is that the entire surface area of the tissue sample on which the enzyme can act is increased. The compartment may be fitted and attached to one port (e.g., an aperture) of a container (e.g., digestion bag) such that a tissue sample introduced into the compartment can directly pass through into the container. The compartment may or may not be removably attached to the container. - The container defines a sterile, sealed interior space that holds the minced tissue sample and fluids. The container may include sealed ports for introducing or dispensing materials and fluids into or from the container. For example, the container may include one or more injection ports for introducing fluids and one or more withdrawal ports for dispensing or suction fluids and materials from the container. Further, in an alternative embodiment, each of the injection ports and withdrawal port can be configured such that fluids and materials can only be moved in one direction to and from the container. Moreover, the ports can be disposed at an opposite end of the container from the compartment, though the ports can also be disposed along any portion of the perimeter of the container. In an embodiment, the ports are not removably secured to the container. Additionally or alternatively, syringes, air vents, capped air vents, or other devices that mate with a luer connection can be attached to the ports. All ports may be swabbable so that sterility is maintained.
- Subsequently, the minced tissue can optionally be digested by, for example exposing it to a chemical or an enzyme. In an embodiment, the minced tissue may be digested by an enzyme, for example, a protease, such as a collagenase, hyaluronidase, or dispase, separately or in combination. The enzyme may be directly introduced into the container, such that the enzyme digests the minced tissue. For example, a syringe, or any other device that can house fluids, materials, or air, can be connected to the container (e.g., via a luer connection) and used to dispense, for example, a protease into the container to digest the minced tissue sample. To enhance digestion of the minced tissue sample, the container can be inverted to circulate the enzyme about the container. Depending on the rate of enzymatic breakdown of the minced tissue sample, the container can be placed at rest and the minced tissue sample can be incubated with the enzyme at 37° C. for a period of time, for example, for about one to three hours, though more or less time is contemplated, to digest the minced tissue sample. Additionally or alternatively, to assist in the incubation process, the container can optionally be periodically mixed with an orbital shaker or moved through a series of rollers or other compression-type device to assist in the break-down of the minced tissue sample within the container. In an example in which the tissue sample is about 10 mL, a user can inject about 10 mL of enzyme into the container, though more or less enzyme is contemplated. Once the minced tissue sample is digested, a digested tissue sample of about 20-30 mL results.
- Before the cells are separated from the minced and/or enzymatically digested tissue, any remaining fragments of undigested tissue are optionally removed to facilitate the subsequent purification of the cells. Depending on their size, undigested tissue can be removed by, for example, physical extraction, decanting, aspiration, sedimentation, or preferably, filtering. Optionally, the undigested tissue that is removed may be stored and/or used for other purposes such as a seeding source for the expansion of stem cells.
-
FIGS. 10A-10D illustrate various embodiments in which separation is achieved by filtration. Specifically,FIGS. 10A-10D depict a fluid passageway that connects the container holding the digested tissue sample to a filter unit which can be removably attached to the container. The filter unit may use a single filter, or a plurality of filters, optionally of decreasing size. Alternatively, a filter may be fitted and disposed in the container such that that the container is divided into two sub-spaces. The filter may be symmetrically or asymmetrically placed within the container. Additionally or alternatively, the filter may be fitted within a port, for example, a withdrawal port. The size of the filter can be about 500 microns, about 250 microns, about 150 microns, about 100 microns, about 70 microns, about 40 microns, or any range thereof, depending on the application. The digested tissue sample, which can be viscous, may be diluted prior to filtering so that the resultant tissue sample can more easily move through the filter into downstream containers or components for further processing. Examples of diluting solutions include phosphate buffered saline (PBS), 5% human serum albumin, saline, heta-starch, and fresh plasma (e.g., autologous plasma). In an embodiment, a syringe, or any other device that can house fluids, is used to dispense a diluting solution into the container via an injection port. In an example in which the digested tissue sample is about 20-30 mL, a user can inject about 250 mL of a diluting solution into the container, though more or less solution is contemplated. As a result, the container holds about 250-300 mL of a diluted, digested tissue sample. Following filtration, the eluate may be propelled, e.g., by vacuum, suction, or gravity, into a second sterile container (e.g., a wash/centrifugation bag) via a fluid passageway preferably regulated by line clamps (e.g., butterfly line clamps). - Isolating cells from diluted, minced and/or enzymatically digested tissue can be accomplished by various mechanisms. In an embodiment, the target cells are isolated from the diluted, minced and/or enzymatically digested tissue by sedimentation. Although gravity sedimentation can be used, the sedimentation process can be accelerated by, for example, centrifugation. The present invention can include customized centrifuge buckets, inserts, and balance weights to ensure proper centrifuge of the system.
- Sedimentation separates the target cells from the diluted, minced and/or enzymatically digested tissue sample. To facilitate cell collection, supernatants substantially free of cells are optionally removed via an outlet port and a fluid passageway preferably regulated by line clamps. The supernatant may be removed by, for example, decanting or aspiration. In an example in which the second sterile container is a compressible bag, the supernatant may be decanted by physically pressing the bag. Alternatively, the supernatant may be removed, e.g., by vacuum, suction, or gravity. Optionally, the supernatant can be removed into a waste container that is connected to the second sterile container through an outlet port and a fluid passageway regulated by line clamps. In an embodiment, the removed supernatant may be stored and/or used for other purposes such as maintaining cells (in culture).
- To collect target cells, a small volume of a diluting solution (e.g., 20 ml of autologous plasma) can be added to resuspend the cell pellet which may collect at the bottom of the second sterile container. As shown in the embodiment depicted in
FIG. 10A , the second sterile container can have a bottom that is tapered to an angle sufficient to facilitate movement of the target cells into a fluid passageway located at the bottom of the container, and optionally into a transfer container (e.g., transfer bag). Alternatively, as depicted inFIG. 10B , target cells may be moved into a fluid passageway located at the side of the container, and optionally into a transfer container. Movement of the cells out of the second sterile container and into the fluid passageway and optionally into a transfer container can be facilitated by vacuum or suction and may be regulated by line clamps. - If needed, the purified, target cells can be used immediately. Typically, however, the cells are cryopreserved for later use. To achieve long-term storage, cells can be transferred from the optional transfer container into a sealable, sterile container amenable to freezing (e.g., cryo-bag). Alternatively, cells can be directly collected from the second sterile container into a freezable container for later use. Cryoprotectants are added to assist in storage and preservation of target cells, and can include, for example, dimethyl sulfoxide (DMSO), albumin, and/or dextran, separately or in combination. Cryoprotectants may be added to the cells within the second sterile container following sedimentation. Alternatively, cryoprotectants may be added to and mixed with the cells within the optional transfer container or within the freezable container for long-term storage and later use.
- In an embodiment, methods for separating minced and/or enzymatically digested tissue from undigested tissue may include two or more filtration steps as depicted in
FIGS. 10C-10D . For example, minced and/or enzymatically digested tissue may be subjected to a first filtration step to remove coarse, undigested tissue. Because the minced and/or enzymatically digested tissue is generally viscous, the tissue can be washed or diluted with an appropriate sterile solution at any stage in the process. For example, after the minced and/or enzymatically digested tissue has been separated from the undigested tissue following the first filtration step, further washes can be performed to further cleanse the tissue prior to a second filtration step. In an embodiment, the second filtration step may utilize a smaller sized filter in order to remove contaminants such as collagen fibers from the minced and/or enzymatically digested tissue. Following the second filtration step, target cells may be collected by sedimentation and moved into an optional transfer bag through a fluid passageway located either at the bottom of the container (FIG. 10C ) or at the side of the container (FIG. 10D ). Alternatively, the cells may be directly collected into a sterile cryo-bag for long-term storage and later use. - Additional exemplary processes for separating minced tissue samples are depicted in
FIGS. 10E-10G . In each of these processes, a tissue sample is placed in a mincer, such as the mincer ofFIG. 7 . In operation, the mincer forces the tissue sample through one or more cutting surfaces and deposits the finely minced tissue on the other side of the cutting surface(s). A saline bag is provided to permit the flushing of the tissue out of the mincer; typically, up to 500 mL of saline may be used for this purpose. When flushed from the mincer, the minced tissue may flow into an optional digestion bag (as shown), where the minced tissue may be enzymatically digested (as described with reference toFIGS. 10A-10D ) prior to further processing. The optional digestion bag is in fluid communication with a dilution bag. Alternatively, if the mechanical mincing has obviated the need for any enzymatic digestion, the minced tissue can flow directly into a dilution bag. The mechanically minced tissue (whether or not subjected to enzymatic digestion) may be viscous. The dilution bag can be mechanically manipulated to encourage the mixing of the tissue and the saline. The dilution bag is also fitted with an optional injection port, permitting the injection of additional saline into the dilution bag as required. - The tissue suspension is then filtered, once the viscosity has been sufficiently reduced. As shown in
FIGS. 10E-G , the suspension passes from the dilution bag into a filter bag having at least one in-bag filter.FIG. 10E depicts an embodiment with a single in-bag filter which retains particles larger than about 40-70 μm. FIG. 1OF depicts an embodiment with a single in-bag filter which retains particles larger than about 150-250 μm. InFIG. 10F , the filtrate from the in-bag filter then passes through a second, in-line filter unit which retains particles larger than about 40-70 μm.FIG. 10G depicts an embodiment in which the filter bag contains two in-bag filters in succession, each in-bag filter having a surface area of at least 300 cm2; the first filter retains particles larger than about 500 μm and the second filter retains particles larger than about 100 μm. In each ofFIGS. 10E-G , the filter bag includes a port permitting the removal of the retentate from the first filter. This retentate can optionally be used as a tissue explant for culturing cells. - The filtrates in
FIGS. 10E-G pass into a centrifugation bag like those depicted inFIGS. 10A-D . Cells are separated from the suspension by sedimentation (e.g. by centrifugation) and are concentrated in the bottom portion of the bag, or in a fluid passageway connected to the bottom portion of the bag. The supernatant can be removed (e.g. by decanting, aspiration, vacuum, suction, or by compressing the bag) through tubing optionally connected to a waste container. The supernatant may be used for other purposes such as maintaining cells in culture. - To collect target cells, a small volume of a diluting solution (e.g., 20 ml of autologous plasma) can be added to resuspend sedimented cells. As shown in
FIGS. 10E-G , the resuspended cells can pass from the centrifugation bag into a transfer bag, optionally after passing through a second filter bag, such as a second filter bag containing a filter having a surface area of at least 100 cm2 and retaining particles greater than about 40 μm, as shown inFIG. 10G . The cells can be transferred to a cryobag and one or more cryoprotectants can be added, such as DMSO, albumin, and/or dextran, as described above forFIGS. 10A-D . - The methods described herein are effective for purifying cells from a variety of solid tissues. For example, the methods described herein can separate cells, such as stem cells, from fat tissue or afterbirth tissue, such as placenta or umbilical cord tissue or, more specifically, a tissue comprising Wharton's Jelly. The purified Wharton's Jelly stem cells can be used to treat or regenerate any of a variety of tissues such as bone, cartilage, fat or muscle. These cells can also facilitate hematopoietic engraftment and have the potential to regulate and suppress immune responses in a host.
- In addition to purified cells, the methods described herein also yield additional useful products. For example, when the cells are separated from the minced and/or enzymatically digested tissue, the remaining, cell-depleted tissue is a rich, sterile solution that can be used for maintaining cells (in culture, for example). Further, any fragments of undigested tissue remaining after a digestion process can also be useful. For example, undigested umbilical cord tissue can be utilized as a seeding source for the expansion of mesenchymal stem cells.
- The terms and expressions employed herein are used as terms and expressions of description and not of limitation, and there is no intention, in the use of such terms and expressions, of excluding any equivalents of the features shown and described or portions thereof. In addition, having described certain embodiments of the invention, it will be apparent to those of ordinary skill in the art that other embodiments incorporating the concepts disclosed herein may be used without departing from the spirit and scope of the invention. Accordingly, the described embodiments are to be considered in all respects as only illustrative and not restrictive. Furthermore, the configurations described herein are intended as illustrative and in no way limiting. Similarly, although physical explanations have been provided for explanatory purposes, there is no intent to be bound by any particular theory or mechanism, or to limit the claims in accordance therewith.
- The entire disclosures of each of the patent documents and scientific articles cited herein are incorporated by reference in their entirety for all purposes.
- The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.
Claims (30)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/547,956 US8967512B1 (en) | 2011-11-08 | 2014-11-19 | Systems and methods for processing cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161557127P | 2011-11-08 | 2011-11-08 | |
PCT/US2012/064130 WO2013070899A1 (en) | 2011-11-08 | 2012-11-08 | Systems and methods for processing cells |
US13/933,034 US8893995B2 (en) | 2011-11-08 | 2013-07-01 | Systems and methods for processing cells |
US14/547,956 US8967512B1 (en) | 2011-11-08 | 2014-11-19 | Systems and methods for processing cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/933,034 Continuation US8893995B2 (en) | 2011-11-08 | 2013-07-01 | Systems and methods for processing cells |
Publications (2)
Publication Number | Publication Date |
---|---|
US8967512B1 US8967512B1 (en) | 2015-03-03 |
US20150079679A1 true US20150079679A1 (en) | 2015-03-19 |
Family
ID=48290538
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/933,034 Active US8893995B2 (en) | 2011-11-08 | 2013-07-01 | Systems and methods for processing cells |
US14/547,966 Active US8967513B1 (en) | 2011-11-08 | 2014-11-19 | Systems and methods for processing cells |
US14/547,956 Active US8967512B1 (en) | 2011-11-08 | 2014-11-19 | Systems and methods for processing cells |
US14/601,500 Active US9145544B2 (en) | 2011-11-08 | 2015-01-21 | Systems and methods for processing cells |
US14/864,258 Active 2032-11-19 US9663760B2 (en) | 2011-11-08 | 2015-09-24 | Systems and methods for processing cells |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/933,034 Active US8893995B2 (en) | 2011-11-08 | 2013-07-01 | Systems and methods for processing cells |
US14/547,966 Active US8967513B1 (en) | 2011-11-08 | 2014-11-19 | Systems and methods for processing cells |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/601,500 Active US9145544B2 (en) | 2011-11-08 | 2015-01-21 | Systems and methods for processing cells |
US14/864,258 Active 2032-11-19 US9663760B2 (en) | 2011-11-08 | 2015-09-24 | Systems and methods for processing cells |
Country Status (14)
Country | Link |
---|---|
US (5) | US8893995B2 (en) |
EP (1) | EP2775928B1 (en) |
JP (1) | JP6159729B2 (en) |
KR (1) | KR102001701B1 (en) |
CN (1) | CN103997974B (en) |
AU (1) | AU2012335746B2 (en) |
CA (1) | CA2862437C (en) |
DK (1) | DK2775928T3 (en) |
ES (1) | ES2725564T3 (en) |
IL (1) | IL232290A (en) |
PL (1) | PL2775928T3 (en) |
PT (1) | PT2775928T (en) |
SG (1) | SG11201402149TA (en) |
WO (1) | WO2013070899A1 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR298901A0 (en) | 2001-02-07 | 2001-03-08 | McComb Foundation, Inc., The | Cell suspension preparation technique and device |
BR112012030678B1 (en) | 2010-06-01 | 2021-10-19 | Auxocell Laboratories, INC | METHOD FOR PURIFICATION OF STEM CELLS FROM WHARTON'S JELLY AND METHOD FOR CULTURE OF MESENCHIMAL STEM CELLS |
AU2013205148B2 (en) * | 2013-03-14 | 2014-10-30 | AVITA Medical Americas, LLC | Systems and methods for tissue processing and preparation of cell suspension therefrom |
US8871159B1 (en) * | 2013-12-17 | 2014-10-28 | Christian Apfel | Preparation of cells, cell aggregates and tissue fragments |
ITRM20130713A1 (en) * | 2013-12-23 | 2015-06-24 | Roberta Foglia | DEVICE FOR THE HANDLING AND TRANSPORT OF AN EYE BULB. |
US10077423B2 (en) | 2014-02-05 | 2018-09-18 | Muffin Incorporated | Compartmented cryopreservation container and uses thereof |
WO2015161057A1 (en) * | 2014-04-18 | 2015-10-22 | Auxocell Laboratories, Inc. | Systems and methods for processing cells |
USD748462S1 (en) | 2014-08-11 | 2016-02-02 | Auxocell Laboratories, Inc. | Centrifuge clip |
US9993748B2 (en) | 2014-08-11 | 2018-06-12 | Auxocell Laboratories, Inc. | Centrifuge clip and method |
CN104472474A (en) * | 2014-11-21 | 2015-04-01 | 广州赛莱拉干细胞科技股份有限公司 | Human adipose tissue-derived stromal cell frozen stock solution |
BR112017012740B1 (en) * | 2014-12-15 | 2021-11-09 | Human Brain Wave S.R.L. | BREAKDOWN DEVICE FOR BIOLOGICAL MATERIAL BREAKDOWN, BREAKDOWN DEVICE MANUFACTURING METHOD FOR BIOLOGICAL MATERIAL BREAKDOWN AND COMBINATION OF A BREAKDOWN DEVICE |
GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
CA3015517A1 (en) * | 2016-03-04 | 2017-09-08 | The Board Of Regents Of The University Of Texas System | Devices and methods for umbilical cord processing |
DE102016114043B3 (en) * | 2016-07-29 | 2017-08-10 | Technische Universität Dresden | Device for isolating stem cells from fetal tissues |
KR20190042688A (en) * | 2016-09-29 | 2019-04-24 | 카오슝 메디칼 유니버시티 | Apparatus for separating cells from tissue |
TWI598150B (en) | 2016-09-30 | 2017-09-11 | 財團法人工業技術研究院 | Grinding machine and slightly gyration device |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
CN108424832B (en) * | 2017-02-15 | 2021-10-08 | Scl生物科技有限公司 | Device with tissue fine-crushing device |
US10996146B2 (en) * | 2017-06-01 | 2021-05-04 | Becton, Dickinson And Company | Devices for dissociating a biological tissue sample and methods of use thereof |
JP6286094B1 (en) * | 2017-07-05 | 2018-02-28 | セルソース株式会社 | Shearing device for fluid containing cellular tissue |
US12023664B2 (en) | 2017-09-01 | 2024-07-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Method and kit for preservation of adipose tissue grafts |
WO2019050882A1 (en) | 2017-09-05 | 2019-03-14 | Board Of Regents Of The University Of Texas System | Devices and methods for umbilical cord processing |
CN111902528B (en) * | 2018-01-24 | 2024-06-28 | 弗劳恩霍夫应用研究促进协会 | Apparatus and method for tissue dissociation |
CN108444745A (en) * | 2018-03-19 | 2018-08-24 | 马奔腾 | A kind of just routine inspection method |
WO2020046651A1 (en) * | 2018-08-29 | 2020-03-05 | Predictive Technology Group, Inc. | Tissue mincers, related systems, and related methods |
US11033295B2 (en) | 2019-05-06 | 2021-06-15 | Tissuemill Technologies Llc | Atraumatically formed tissue composition, devices and methods of preparation and treatment |
KR102487903B1 (en) * | 2019-06-02 | 2023-01-12 | (주)카스 인 바이오 | Method for micronizing a soft biological tissue and biological tissue graft thereof |
CN110646233B (en) * | 2019-11-22 | 2020-04-07 | 广州赛太特生物医学科技有限公司 | Cell diagnosis is with quantitative sampling device |
CA3164986A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
CN111134336B (en) * | 2020-01-16 | 2022-11-15 | 吉林农业科技学院 | Extraction element of dragon fruit peel active ingredient |
US20220349784A1 (en) * | 2020-01-20 | 2022-11-03 | Genetrack Biolabs Inc. | Methods and devices for mincing biological tissue |
US11786266B2 (en) | 2020-02-14 | 2023-10-17 | Arthrex, Inc. | Variable particle size tissue collector |
US11987787B2 (en) | 2020-07-22 | 2024-05-21 | AVITA Medical Americas, LLC | Devices, methods, and kits for preparing a cell suspension |
WO2023181636A1 (en) | 2022-03-23 | 2023-09-28 | 富士フイルム株式会社 | Cell isolation method and cell isolation apparatus |
WO2023209039A2 (en) | 2022-04-27 | 2023-11-02 | Gerlach, Jörg C. | Tissue structure isolation using a micro-cutting device and uses of resulting micro-cubes of tissue |
DE202023002794U1 (en) * | 2022-12-27 | 2024-07-15 | AVITA Medical Americas, LLC | Cassette for the preparation of a regenerative epidermal suspension |
NL2034251B1 (en) | 2023-03-02 | 2024-09-09 | Biostem Tech Inc | Human umbilical cord composition for treatment of peyronie's disease |
WO2024151724A1 (en) | 2023-01-11 | 2024-07-18 | Biostem Technologies, Inc. | Human umbilical cord composition for use in the treatment of peyronie's disease |
WO2024151932A1 (en) * | 2023-01-13 | 2024-07-18 | Omni International, Inc. | Tissue dissociation using internally threaded tubes |
CN117305078B (en) * | 2023-09-25 | 2024-08-27 | 成都赛恩吉诺生物科技有限公司 | Tissue dissociation method |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3380499A (en) | 1966-05-05 | 1968-04-30 | Army Usa | Pulsating tissue-homogenizer |
GB1152418A (en) | 1967-01-30 | 1969-05-21 | Brown Electronics Ltd Ag | An Improved Homogeniser |
US3666187A (en) | 1970-05-13 | 1972-05-30 | Us Health Education & Welfare | Laboratory homogenizer |
US4151959A (en) | 1978-01-30 | 1979-05-01 | Clifford E. Rawlings | Apparatus for comminuting pulverizable material |
US4307846A (en) | 1979-10-09 | 1981-12-29 | Spelsberg Thomas C | Continuous flow tissue homogenizer |
US4509695A (en) | 1983-07-18 | 1985-04-09 | Spectrum Medical Industries, Inc. | Tissue pulverizer |
JPS6143982A (en) | 1984-08-07 | 1986-03-03 | Yamato Scient Co Ltd | Continuous flow homogenizer |
JPS6143981A (en) | 1984-08-07 | 1986-03-03 | Yamato Scient Co Ltd | Continuous flow homogenizer |
US4828395A (en) | 1985-02-21 | 1989-05-09 | Yamato Scientific Company, Limited | Continuous flow type homogenizer |
US6863431B2 (en) | 1992-03-30 | 2005-03-08 | Omni International, Inc. | Disruptor device which eliminates cross contamination |
EP0590219A1 (en) * | 1992-10-02 | 1994-04-06 | SULZER Medizinaltechnik AG | Method for comminuting soft tissue and means for carrying out the method |
JPH06143981A (en) | 1992-10-30 | 1994-05-24 | Nippondenso Co Ltd | Vehicle immediate heating device |
JPH06143982A (en) | 1992-11-04 | 1994-05-24 | Matsushita Electric Ind Co Ltd | Vehicle auxiliary heating equipment |
IT1260682B (en) * | 1993-09-28 | 1996-04-22 | Consult T S S N C Di Roggero G | MECHANICAL SHREDDER DEVICE OF BIOLOGICAL MATERIAL |
DE19729028C1 (en) * | 1997-07-08 | 1999-05-06 | Fraunhofer Ges Forschung | Device and method for isolating cell material from a tissue association and / or a liquid |
CN2340373Y (en) * | 1997-10-31 | 1999-09-29 | 山东医科大学附属医院 | Rotary cutting instrument for cell sample |
US6120474A (en) | 1997-12-15 | 2000-09-19 | Nissho Corporation | Blood component-recovering apparatus and a method for recovering blood components using the same |
US6471392B1 (en) | 2001-03-07 | 2002-10-29 | Holl Technologies Company | Methods and apparatus for materials processing |
US7399633B2 (en) | 2000-10-27 | 2008-07-15 | Fred Hutchinson Cancer Research Center | Methods for immortalizing cells |
US6634577B2 (en) | 2000-12-20 | 2003-10-21 | Tsukuba Food Science, Inc. | Crusher, process for preparing and testing materials and apparatus therefor |
JP2004536794A (en) | 2001-04-09 | 2004-12-09 | メドトロニック、インコーポレイテッド | Method for separating blood components using microcentrifuge and method for using the same |
US6579219B2 (en) | 2001-04-09 | 2003-06-17 | Medtronic, Inc. | Centrifuge bag and methods of use |
US20020197631A1 (en) | 2001-04-26 | 2002-12-26 | Lawrence Nathan P. | Multichamber device and uses thereof for processing of biological samples |
JP3451285B2 (en) | 2001-05-07 | 2003-09-29 | 有限会社美粒研 | Mixing / crushing fine-graining apparatus and method for finely-granulating a substance using the same |
US20030054331A1 (en) | 2001-09-14 | 2003-03-20 | Stemsource, Inc. | Preservation of non embryonic cells from non hematopoietic tissues |
AU2002357135C1 (en) | 2001-12-07 | 2009-01-22 | Macropore Biosurgery, Inc. | Systems and methods for treating patients with processed lipoaspirate cells |
US20030161818A1 (en) * | 2002-02-25 | 2003-08-28 | Kansas State University Research Foundation | Cultures, products and methods using stem cells |
US7241281B2 (en) | 2002-04-08 | 2007-07-10 | Thermogenesis Corporation | Blood component separation method and apparatus |
US7060494B2 (en) | 2002-04-09 | 2006-06-13 | Reliance Life Sciences Pvt. Ltd. | Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the preparation thereof |
NZ518432A (en) | 2002-04-16 | 2004-09-24 | Agres Ltd | A homogeniser and method of cleaning same. |
US20040158226A1 (en) * | 2003-02-07 | 2004-08-12 | Genoptix, Inc. | Syringe tissue sieve |
ES2351386T3 (en) | 2003-02-11 | 2011-02-03 | John E. Davies | PROGENITATING CELLS FROM THE WHARTON GELATINE OF HUMAN UMBILICAL CORD. |
US7794408B2 (en) * | 2003-03-28 | 2010-09-14 | Ethicon, Inc. | Tissue collection device and methods |
US20040197375A1 (en) | 2003-04-02 | 2004-10-07 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
US20040203142A1 (en) | 2003-04-14 | 2004-10-14 | Reliance Life Sciences Pvt. Ltd. | Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes |
US6817750B1 (en) | 2003-08-26 | 2004-11-16 | Homeland Housewares, Llc | Individualized blender |
US7441944B2 (en) * | 2003-08-26 | 2008-10-28 | Homeland Housewares, Llc | Drinking extension for blender container |
US8034003B2 (en) * | 2003-09-11 | 2011-10-11 | Depuy Mitek, Inc. | Tissue extraction and collection device |
US7611473B2 (en) | 2003-09-11 | 2009-11-03 | Ethicon, Inc. | Tissue extraction and maceration device |
US7052172B2 (en) | 2003-09-15 | 2006-05-30 | Omni International, Inc. | Combination low-shear mixer and high-shear homogenizer |
KR20060102325A (en) | 2003-09-22 | 2006-09-27 | 바텔리 메모리얼 인스티튜트 | Tissue dissociation device |
IE20030856A1 (en) | 2003-11-14 | 2005-06-15 | Enfer Technology Ltd | Sample homogeniser |
US7172334B2 (en) | 2003-12-11 | 2007-02-06 | Conair Corporation | Hand held blender |
TWI255738B (en) * | 2003-12-31 | 2006-06-01 | Ind Tech Res Inst | Tissue pulverizer |
US20050229795A1 (en) * | 2004-04-20 | 2005-10-20 | Priscilla Stuckey | Battery operated portable juicer and blender |
EP1839027B1 (en) | 2005-01-21 | 2016-10-19 | Medic Tools AG | One-way mixer, homogeniser, extractor, fractioner or slurry producer |
US7923007B2 (en) | 2005-08-08 | 2011-04-12 | Academia Sinica | Brain tissue damage therapies |
EP1947170B1 (en) | 2005-10-21 | 2018-08-08 | Kaneka Corporation | Stem cell separating material and method of separation |
WO2007059084A2 (en) | 2005-11-14 | 2007-05-24 | The New England Medical Center Hospitals, Inc. | Methods for preparing cord matrix stem cells (cmsc) for long term storage and for preparing a segment of umbilical cord for cryopreservation |
BRPI0621107A2 (en) | 2005-12-22 | 2011-11-29 | Jane Ennis | viable cell retrieval method of umbilical cord tissue, preservation of viability of cells present in umbilical cord tissue, umbilical cord tissue and viable hucpvcs recovery method |
EP1889654A1 (en) | 2006-02-03 | 2008-02-20 | Wockhardt Limited | Silicone oil-in-water emulsions-formulation, production and use |
CA2644508A1 (en) | 2006-03-01 | 2007-09-07 | The Regenerative Medicine Institute | Compostions and populations of cells obtained from the umbilical cord and methods of producing the same |
JP5259929B2 (en) * | 2006-04-25 | 2013-08-07 | 株式会社カネカ | Cell separation apparatus suitable for collecting stem cells from adipose tissue, and method thereof |
WO2007130826A2 (en) | 2006-05-04 | 2007-11-15 | Ge Healthcare Bio-Sciences Ab | Separation of cells |
CA2649234C (en) | 2006-05-04 | 2015-07-14 | Pierluigi Reschiglian | Method and device to fractionate stem cells |
US20090081171A1 (en) | 2006-08-11 | 2009-03-26 | Yu-Show Fu | Cell system for alleviating syndromes of Parkinson's disease in a mammal |
WO2008021391A1 (en) | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
KR20080037883A (en) | 2006-10-27 | 2008-05-02 | 세원셀론텍(주) | Using method and medical kit |
US20080118477A1 (en) | 2006-11-09 | 2008-05-22 | Rush University Medical Center | Umbilical cord mesenchymal stem cells support cord blood hematopoiesis |
US20090124007A1 (en) | 2006-11-15 | 2009-05-14 | Seoul National University Industry Foundation | Method for the Simultaneous Primary-Isolation and Expansion of Endothelial Stem/Progenitor Cell and Mesenchymal Stem Cell Derived From Mammal Including Human Umbilical Cord |
US20080132803A1 (en) | 2006-11-30 | 2008-06-05 | Hyman Friedlander | Method and system for doing business by mining the placental-chord complex |
AU2007332799A1 (en) | 2006-12-07 | 2008-06-19 | Teva Pharmaceutical Industries Ltd. | Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue |
US20080305148A1 (en) | 2007-03-19 | 2008-12-11 | National Yang Ming University | Treatment of spinal injuries using human umbilical mesenchymal stem cells |
US20110002883A1 (en) | 2007-04-10 | 2011-01-06 | Petrikovsky Boris M | Therapeutic preparations containing wharton's jelly |
US20090068153A1 (en) | 2007-09-06 | 2009-03-12 | Vitelli Francesca P | Cell composition for tissue regeneration |
CA2736663C (en) | 2007-09-07 | 2018-01-02 | Surgical Biologics, Llc. | Placental tissue grafts and improved methods of preparing and using the same |
CA2630708C (en) | 2007-09-13 | 2017-08-01 | Clifford L. Librach | Method of isolation and use of cells derived from first trimester umbilical cord tissue |
US20110158969A1 (en) | 2008-02-28 | 2011-06-30 | Henry Ford Health System | Compositions and methods for using stromal cells to enhance treatment of central nervous system injuries |
US20090232781A1 (en) | 2008-03-13 | 2009-09-17 | Yu-Show Fu | Treatment of liver diseases through transplantation of human umbilical mesenchymal stem cells |
US20090232782A1 (en) | 2008-03-14 | 2009-09-17 | Yu-Show Fu | Method for treating brain ischemic injury through transplantation of human umbilical mesenchymal stem cells |
US20090291061A1 (en) | 2008-05-21 | 2009-11-26 | Riordan Neil H | Stem cell therapy for blood vessel degeneration |
US20100098675A1 (en) | 2008-05-30 | 2010-04-22 | Nikolai Tankovich | Methods for reducing the side effects of ophthalmic laser surgery |
WO2010021993A1 (en) * | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
BRPI0822802A2 (en) | 2008-10-10 | 2015-09-01 | Histocell Sl | Biomaterial in the form of injectable hydrogel, biomaterial derived from the human umbilical cord, process for obtaining biomaterial, process for obtaining biomaterial obtained and use of biomaterial |
EP2367932B1 (en) | 2008-11-19 | 2019-06-12 | Celularity, Inc. | Amnion derived adherent cells |
CN101748096B (en) | 2008-12-17 | 2013-03-13 | 北京汉氏联合生物技术有限公司 | Sub totipotential stem cell and preparation method and application thereof |
US20100247495A1 (en) | 2009-03-30 | 2010-09-30 | Tom Ichim | Treatment of Muscular Dystrophy |
WO2010124235A1 (en) | 2009-04-23 | 2010-10-28 | Cytori Therapeutics, Inc. | Use adipose tissue-derived regenerative cells in the modulation of inflammation in the pancreas and in the kidney |
US20120141595A1 (en) | 2009-08-25 | 2012-06-07 | Tissuetech, Inc. | Umbilical cord amniotic membrane products |
KR101316573B1 (en) | 2009-10-27 | 2013-10-15 | 도병록 | System and unit for extracting regenerative cells |
JP2013514072A (en) | 2009-12-18 | 2013-04-25 | シー.ビー.ビー.ライフライン バイオテク リミテッド | Methods for isolating mononuclear cells containing a subpopulation of mesenchymal progenitor cells and vascular cells containing a subpopulation of endothelial progenitor cells from umbilical cord tissue |
MX344460B (en) | 2009-12-23 | 2016-12-14 | Cytovera Inc * | A system and method for particle filtration. |
CA2787050A1 (en) | 2010-01-14 | 2011-07-21 | Organogenesis, Inc. | Bioengineered tissue constructs and methods for producing and using thereof |
US8574614B2 (en) | 2010-02-04 | 2013-11-05 | Hwa-Chang Liu | Surgical grafts for repairing chondral defects |
US20120315259A1 (en) | 2010-02-18 | 2012-12-13 | Hyman Friedlander | Method and composition for skin care comprising cord blood serum or plasma or components thereof |
WO2011117821A1 (en) * | 2010-03-23 | 2011-09-29 | Carlo Tremolada | A device and a method for preparing a tissue |
US8415149B2 (en) | 2010-05-06 | 2013-04-09 | Gwo Xi Stem Cell Applied Technology Co., Ltd. | Hepatic progenitor cells and uses thereof |
US8809054B2 (en) | 2010-05-12 | 2014-08-19 | Xpand Biotechnology B.V. | Cell-culture-bag |
US20120270314A1 (en) | 2011-04-19 | 2012-10-25 | Buddhist Tzu Chi General Hospital | Non-tumorigenic expansion of pluripotent stem cells |
US20120276518A1 (en) | 2011-04-26 | 2012-11-01 | John Archie Gillis | Method and Device for Perfusing Tissue by ExVivo Attachment to a Living Organism |
US20120276215A1 (en) | 2011-04-26 | 2012-11-01 | Riordan Neil H | Therapeutic Conditioned Media |
US20130034524A1 (en) | 2011-08-03 | 2013-02-07 | Siamak Agha-Mohammadi | Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate |
TWI535377B (en) | 2011-09-01 | 2016-06-01 | Storage, culture and application of umbilical cord tissue and its derived cells |
-
2012
- 2012-11-08 AU AU2012335746A patent/AU2012335746B2/en active Active
- 2012-11-08 JP JP2014540230A patent/JP6159729B2/en active Active
- 2012-11-08 PT PT12847676T patent/PT2775928T/en unknown
- 2012-11-08 WO PCT/US2012/064130 patent/WO2013070899A1/en active Application Filing
- 2012-11-08 DK DK12847676.9T patent/DK2775928T3/en active
- 2012-11-08 SG SG11201402149TA patent/SG11201402149TA/en unknown
- 2012-11-08 KR KR1020147014981A patent/KR102001701B1/en active IP Right Grant
- 2012-11-08 EP EP12847676.9A patent/EP2775928B1/en active Active
- 2012-11-08 CA CA2862437A patent/CA2862437C/en active Active
- 2012-11-08 CN CN201280055019.5A patent/CN103997974B/en active Active
- 2012-11-08 ES ES12847676T patent/ES2725564T3/en active Active
- 2012-11-08 PL PL12847676T patent/PL2775928T3/en unknown
-
2013
- 2013-07-01 US US13/933,034 patent/US8893995B2/en active Active
-
2014
- 2014-04-28 IL IL232290A patent/IL232290A/en active IP Right Grant
- 2014-11-19 US US14/547,966 patent/US8967513B1/en active Active
- 2014-11-19 US US14/547,956 patent/US8967512B1/en active Active
-
2015
- 2015-01-21 US US14/601,500 patent/US9145544B2/en active Active
- 2015-09-24 US US14/864,258 patent/US9663760B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2725564T3 (en) | 2019-09-24 |
AU2012335746A1 (en) | 2014-05-15 |
US20150132851A1 (en) | 2015-05-14 |
JP6159729B2 (en) | 2017-07-05 |
SG11201402149TA (en) | 2014-06-27 |
DK2775928T3 (en) | 2019-05-27 |
US8967512B1 (en) | 2015-03-03 |
US20160083691A1 (en) | 2016-03-24 |
EP2775928A1 (en) | 2014-09-17 |
US9145544B2 (en) | 2015-09-29 |
CN103997974B (en) | 2016-06-08 |
AU2012335746B2 (en) | 2017-04-27 |
JP2014534817A (en) | 2014-12-25 |
EP2775928B1 (en) | 2019-02-20 |
CA2862437A1 (en) | 2013-05-16 |
US8967513B1 (en) | 2015-03-03 |
US20130295673A1 (en) | 2013-11-07 |
US8893995B2 (en) | 2014-11-25 |
US20150079672A1 (en) | 2015-03-19 |
CN103997974A (en) | 2014-08-20 |
US9663760B2 (en) | 2017-05-30 |
KR20140105730A (en) | 2014-09-02 |
KR102001701B1 (en) | 2019-10-01 |
PL2775928T3 (en) | 2019-09-30 |
IL232290A0 (en) | 2014-06-30 |
WO2013070899A1 (en) | 2013-05-16 |
IL232290A (en) | 2017-11-30 |
PT2775928T (en) | 2019-05-30 |
EP2775928A4 (en) | 2015-07-22 |
CA2862437C (en) | 2018-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9663760B2 (en) | Systems and methods for processing cells | |
JP2014534817A5 (en) | ||
EP2254991B1 (en) | A system and process for separating a material | |
WO2015161057A1 (en) | Systems and methods for processing cells | |
US9920301B2 (en) | Native Wharton's jelly stem cells and their purification | |
KR20220004086A (en) | Systems and methods for extraction and cryopreservation of bone marrow | |
US8673639B2 (en) | Methods for isolating stem cells | |
Pawitan et al. | Simple lipoaspirate washing using a coffee filter | |
EP2931330A1 (en) | Point of care isolation and concentration of blood cells | |
CN112574947A (en) | In-vitro culture method of chondrocytes | |
WO2021003257A1 (en) | Methods and compositions for collecting and using placental tissue cells and placental blood cells | |
JP3246958U (en) | System for isolating, storing and using cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AUXOCELL LABORATORIES, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAGHIZADEH, ROUZBEH R.;REEL/FRAME:034228/0463 Effective date: 20130712 Owner name: AUXOCELL LABORATORIES, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEADE, JOHN;REEL/FRAME:034228/0522 Effective date: 20100806 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: 7.5 YR SURCHARGE - LATE PMT W/IN 6 MO, SMALL ENTITY (ORIGINAL EVENT CODE: M2555); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
AS | Assignment |
Owner name: BIOSTEM TECHNOLOGIES, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AUXOCELL LABORATORIES, INC.;REEL/FRAME:063063/0774 Effective date: 20230216 |
|
AS | Assignment |
Owner name: AUXOCELL OPERATIONS, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOSTEM TECHNOLOGIES, INC.;REEL/FRAME:068778/0860 Effective date: 20240930 |